James Alexander, ECCO-IBD 2022: COVID-19 Vaccination in Patients with IBD on Immunosuppressants
We caught up with Dr James Alexander (Imperial College London, London, UK) to discuss the impact of immunosuppressant drugs on COVID-19 vaccine responses in patients with IBD.
The abstract ‘COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab’ (Presentation no. OP21) was presented at the 17th Congress of ECCO, February 16-19, 2022!
- What was known about the impact of immunosuppressant drugs on COVID-19 vaccine-induced antibody responses in patients with IBD? (0:14)
- What were the aims and methodology of your study? (1:55)
- What were the study findings? (3:14)
- On the basis of these data, what are your recommendations for vaccines in IBD patients taking immunosuppressant drugs? (4:33)
Disclosures: James Alexander discloses receiving grant/ research support from Pfizer Ltd.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual meeting 2022.
Share this Video
Related Videos In Digestive Disorders
Stefan Schreiber, ECCO’23: Corticosteroid-free remission with etrasimod in ulcerative colitis – analysis of the ELEVATE UC 52 study
The ELEVATE UC 52 study (NCT03945188) investigated the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis, a recent analysis of the study was presented at ECCO’23 looking at corticosteroid (CS)-free remission as a clinical endpoint. In this touchIMMUNOLOGY interview, we spoke with Dr. Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, […]
Stefan Schreiber, ECCO’23: Current treatment paradigm for ulcerative colitis and corticosteroid-free remission as a treatment goal
The current treatment paradigm for ulcerative colitis (UC) includes amino salicylic acid as a first line treatment followed by corticosteroids, targeted treatment and rectal topical therapy; however, with corticosteroids (CS) impacting long-term health, CS-free remission has become a long-term goal in treatment. Etrasimod is an S1P receptor modulator, recently investigated for the treatment of UC […]
Jean-Frederic Colombel, ECCO 2023: A sub-analysis investigating upadacitinib for rapid symptom relief in Crohn’s disease
The U-EXCEL (NCT03345849) and U-EXCEED (NCT03345836) phase 3 studies investigated the efficacy and safety of upadacitinib, an oral, selective JAK inhibitor in patients with moderate-to-severe Crohn’s disease. touchIMMUNOLOGY were delighted to speak with Dr. Jean-Frederic Colombel (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to discuss his sub-analysis of the data from U-EXCEL […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!